How Rinvoq and Skyrizi Will Drive 21.5% EPS Growth at Q2 Print

Biotech and pharma execs are watching AbbVie's Q2 report for clues on the next chapter of immunology leadership. Rinvoq and Skyrizi—already mega-blockbusters—are being positioned to dominate an autoimmune market projected to exceed $150 billion. With a $10.9 billion bolt-on acquisition of Apogee, AbbVie is betting heavily on next-gen targets like IL-4, IL-13, and TSLP to extend its reign, making this earnings call a critical read on pipeline ROI.

AbbVie stands at a critical juncture ahead of its July 31 second-quarter earnings report, with the pharmaceutical giant poised to either extend its post-Humira recovery or face a sharp investor reset. The consensus estimate of $3.61 per share represents a 21.5% year-over-year increase, driven largely by the continued uptake of immunology successors Rinvoq and Skyrizi. These therapies have largely offset the revenue drain from Humira's biosimilar erosion, which began in 2023 and has cost AbbVie billions in annual sales. The Q1 2026 earnings beat—which surprised analysts—was fueled by exactly this same dynamic, and the trend appears intact for Q2.

“

The consensus estimate of $3.61 per share represents a 21.5% year-over-year increase, driven largely by the continued uptake of immunology successors Rinvoq and Skyrizi.

Yet management's recent warning about one-time charges looms large. While the precise nature of these charges was not detailed, pharmaceutical companies often book restructuring, acquisition, or legal settlement costs in a given quarter. AbbVie's pending $10.9 billion acquisition of Apogee Therapeutics, announced in June 2026, could be a source of such charges, as integration and deal-related accounting adjustments trickle through. Apogee itself is an immunology-focused biotech with a pipeline of novel antibody therapies aimed at inflammatory diseases, signaling AbbVie's determination to deepen its foothold in the lucrative immunology market, which already accounts for the lion's share of its revenue.

The stock's recent rally—pushing it near multi-year highs—has raised the stakes. With a forward dividend yield of approximately 2.7%, AbbVie remains a favorite among income investors, but the share price appreciation has compressed the yield modestly. If earnings merely meet expectations, investors may take profits, particularly if the one-time charges are larger than anticipated or if forward guidance disappoints. Even a beat could trigger a sell-off if the market perceives it as already priced in. This "sell the news" risk is heightened by the crowded long positioning typical of a widely followed large-cap stock.

From a strategic perspective, AbbVie's pivot to immunology is well-timed. The global autoimmune disease treatment market is projected to exceed $150 billion by 2027, and Rinvoq and Skyrizi are established blockbusters with expanding indications. The Apogee deal adds early- to mid-stage assets that could sustain growth into the 2030s, reducing the company's historical reliance on a single molecule like Humira. However, the integration process carries execution risk, and the $10.9 billion price tag—representing a significant premium over Apogee's pre-announcement market cap—raises questions about capital allocation and return on investment.